Dr Reddy’s announces launch of USFDA-approved Icosapent Ethyl capsules in US market
Dr Reddy’s Laboratories Ltd, an Indian multinational pharmaceutical company, announced today the launch of USFDA-approved Icosapent Ethyl capsules in 1 mg strength in the US market.
The approved capsules are directed to be used as a supplement with a diet for reducing triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.
However, the medicine can’t be used as an adjunct to maximally tolerated statin therapy for minimising the risk of myocardial infarction, stroke, coronary revascularisation, and unstable angina needing hospitalisation in adult patients, who are diagnosed with elevated triglyceride (TG) levels (≥ 150 mg/dL). In addition to this, the capsules can’t be used by patients with established cardiovascular disease or diabetes mellitus and two or more additional risk factors for cardiovascular disease.
The newly-launched Icosapent Ethyl capsules are available in 1-gram capsules in a bottle count of 120 capsules.
At 12.55 pm on Tuesday, the share price of Dr Reddy’s Laboratories Ltd was trading at Rs 5,295.90, an increase of 0.31 per cent over its previous day’s closing price of Rs 5,279.60 on BSE.